Experimental cell therapy targets lung scarring in End-Stage disease

This early-stage trial tests a new cell therapy for people with end-stage idiopathic pulmonary fibrosis (IPF), a disease that causes severe lung scarring and breathing failure. The therapy uses specially engineered immune cells to target and reduce scarring in the lungs. The study will enroll 8 adults to check if the treatment is safe and can improve lung function.